In testimony before Congress last week, by DEA acting administrator Robert Patterson opined that the medicalization of cannabis is exacerbating opioid abuse. But when prompted to provide evidence in support of the agency’s position, he acknowledged that he could not.
Patients enrolled in New York state’s medical cannabis program reduce their use of opioids and spend less money on prescription medications, according to data published online in the journal Mental Health Clinician. “After three months treatment, medical cannabis improved [subjects’] quality of life, reduced pain and opioid use, and lead to cost savings,” authors concluded.
Maine lawmakers voted overwhelmingly to override Republican Gov. Paul LePage’s veto of LD 1719; the enactment of the legislation establishes a framework for the retail sale of marijuana to adults, but also amends numerous provisions of the 2016 voter-approved measure — including those specific to home grow limits and taxation.
The frequent use of cannabis is not associated with changes in brain structure, according to data published online ahead of print in the journal Addiction. Authors reported, “[N]ormal variation in cannabis use is statistically unrelated to individual differences in brain morphology as measured by subcortical volume.”
A bipartisan coalition of over two-dozen federal lawmakers, including House Judiciary Chairman Bob Goodlatte (R-VA) and Matt Gaetz (R-FL), are backing newly introduced legislation — The Medical Cannabis Research Act of 2018 — to facilitate federally-approved clinical trials involving cannabis. Passage of this act would end the University of Mississippi’s existing monopoly on the growth of cannabis for clinical research purposes by requiring the licensing of additional manufacturers.
Election officials have confirmed that proponents of a statewide ballot measure, The Michigan Regulation and Taxation of Marihuana Act, have gathered a sufficient number of signatures from registered voters to place it on the electoral ballot this November.
United States Rep. Timothy Waltz (D-MN), along with over 30 bipartisan co-sponsors, has introduced legislation, HR 5520: The VA Medicinal Cannabis Research Act of 2018, to facilitate federally-sponsored clinical research into the safety and efficacy of medical cannabis among veterans.
Republican Senator Cory Gardner (CO) says that he has received a verbal commitment from President Donald Trump specifying that the administration will not take action to disrupt marijuana markets in states that legally regulate the substance. In response to the administration’s pledge, NORML Director Erik Altieri stated: “[I]t is time for Congress to do its part and swiftly move forward bipartisan legislation that explicitly provides states with the authority and autonomy to set their own marijuana policies absent the fear of federal incursion.”
United States Senate Majority Leader Mitch McConnell (R-KY), along with Oregon Democrat Ron Wyden introduced legislation today to remove low THC hemp from the federal Controlled Substances Act and amend federal regulations to better facilitate industrial hemp production, research, and commerce.